Introduction {#j_jomb-2016-0030_s_001}
============

The mechanism of atherosclerosis has been well investigated since 1950 in different aspects such as lipid mechanism ([@j_jomb-2016-0030_ref_001]), role of oxidative stress ([@j_jomb-2016-0030_ref_002]), and endothelial function ([@j_jomb-2016-0030_ref_003], [@j_jomb-2016-0030_ref_004]). It is well characterized by chronic oxidative stress and inflammatory changes in the vascular tissue play a crucial role in coronary atherosclerosis pathogenesis ([@j_jomb-2016-0030_ref_002]). Endothelium maintains the balance between vasodilation and vasoconstriction, inhibition and stimulation of smooth muscle cell proliferation, migration, thrombogenesis and fibrinolysis ([@j_jomb-2016-0030_ref_005], [@j_jomb-2016-0030_ref_006]). When the vasomotor functions of endothelium are impaired, endothelial dysfunction occurs and causes damage to the wall. Damage to the endothelium promotes substantial events and provokes atherosclerosis by increasing endothelial permeability, platelet aggregation, leukocyte adhesion ([@j_jomb-2016-0030_ref_002]).

Endothelial cells, circulating platelets and proteins of the coagulation and fibrinolytic systems are known to contribute to the hemostatic processes. Activation level of platelet is shown by the variation of platelet activity and functions in inflammatory diseases, specifically in CVD. Platelets localized in intravascular compartment and platelet-specific secretory granule products are also increased in CVD. This situation shows the intravascular platelet activation.

There has been growing interest in the links between endothelial dysfunction and CV risk factors. Several studies have shown that CV risk factors can promote development of endothelial dysfunction in persons with no clinical evidence of coronary disease. Traditional risk factors such as hypercholesterolemia, hypertension, smoking, family history, diabetes, obesity which predispose a person to the development of atherosclerosis are also associated with endothelial dysfunction ([@j_jomb-2016-0030_ref_007]--[@j_jomb-2016-0030_ref_009]).

Among the traditional risk factors, sex has a crucial importance in the progression of cardiovascular diseases due to preponderance of mortality and morbidity rates across genders. The progression rate of vascular diseases also differs among genders. These differences may also suggest gender-based mechanisms underlying cardiovascular diseases. Differences in coronary flow reserve and atheroma burden have also been observed between males and females. Some studies reported that women had slightly lower coronary flow reserves even with normal angiographic results ([@j_jomb-2016-0030_ref_010]). Beside, the role of gender in atherosclerosis still remains unclear.

In some studies, brachial FMD has been stated as an independent predictor of cardiovascular events ([@j_jomb-2016-0030_ref_011], [@j_jomb-2016-0030_ref_012]). Despite the data linking FMD and cardiovascular diseases, most of them are limited primarily to subjects with high risk for CVD events. In daily practice we use traditional CV risk factors for predicting CVD risk, however, impact of untraditional CV risk factors such as endothelial dysfunction markers is not clear.

Current approaches support the assumption that combinations of non-invasive vascular indices with traditional and untraditional CV risk factors may serve as cumulative risk markers for the assessment of subclinical vascular diseases. To contribute the current approach, we assessed the relationship between FMD and endothelial dysfunction biomarkers among genders in low CV risk indivuals.

Material and Methods {#j_jomb-2016-0030_s_002}
====================

One hundred thirty-six patients applied to Cerrahpasa Medical School Department of Family Practice at University of Istanbul and were enrolled in this study. The study protocol was previously reviewed and approved by the Ethics Committee of University of Istanbul, Cerrahpasa Medical School (Issue Number: 12793, April 5, 2011). Written informed consent was obtained from all participants. All blood samples were collected in accordance with the Declaration of Helsinki. Patients with chronic liver disease, chronic renal failure, cancer, serious systemic infections, chronic lung disease, or any endocrine disease were excluded. CV risk of the patients was evaluated according to the European Society of Cardiology (ESC) risk score system which includes age, blood pressure, smoking, total cholesterol and gender ([@j_jomb-2016-0030_ref_013], [@j_jomb-2016-0030_ref_014]). Among 136 patients, 92 low CV risk individuals were selected. Total cholesterol (TC), high density lipoprotein (HDL), low density lipoprotein (LDL), triglyceride (TG) and high sensitive C-reactive protein (hs-CRP) levels were analyzed in the autoanalyzer of the faculty's central biochemistry laboratory.

Plasma oxidized LDL levels (Wuhan EIAAB Science, Wuhan China), ADMA levels (Wuhan EIAAB Science, Wuhan China), E-Selectin levels (Wuhan EIAAB Science, Wuhan China), vWF levels (Assaypro, Missouri, USA), endothelial nitric oxide synthase (eNOS) levels (Wuhan EIAAB Science, Wuhan China) were measured. Platelet function was evaluated by an ADP-induced platelet aggregation method conventionally measured by optical density ([@j_jomb-2016-0030_ref_015]). Blood was obtained from venipuncture and collected into vacutainer tubes containing 3.2% sodium citrate for platelet function. Platelet functional studies were completed within 2 hours of blood drawing.

Platelet reactivity *ex vivo* was assessed by PRP (platelet rich plasma) aggregometer using a Chrono-Log after stimulating samples with arachidonic acid (0.5 mmol/L), collagen (1 μg/mL), or adenosine diphosphate (ADP) (1 μmol/L). Peak aggregation within 5 minutes of agonist stimulation was recorded in ohms and 5 μL od ADP was added to 495 μL sample for a final concentration of 10 μmol/L. PRP (500 μmol/L) was put in tube 3×10^8^ platelet/mL was included. Then, the tube was transferred to the sample containers of the aggregometer and kept at 37 °C for 3 minutes, afterwhich it was treated with 1 μmol/L ADP (Chrono log) for 3 minutes. Platelet aggregation was observed and the aggregation curve taken from the aggregometer (Chronolog 500, USA) was evaluated in terms of slope and amplitude percentage (slope Ω, amplitude activity %) ([@j_jomb-2016-0030_ref_016], [@j_jomb-2016-0030_ref_017]). Sialic acid was measured by a colorimetric method ([@j_jomb-2016-0030_ref_018]).

We evaluated endothelial function based on the measurement of flow-mediated dilatation (FMD) using brachial artery ultrasonography. Brachial artery ultrasonography was performed in the Echocardiography Laboratory, Department of Cardiology, Cerrahpasa Medical School. A transducer connected to a Vingmed System V ultrasound instrument (GE Healthcare, Little Chalfont, Buckinghamshire, UK) at the appropriate frequency was used to achieve this aim. After 12 hours of fasting, examination was performed by two experienced practitioners in a quiet room at 20--24 °C. Longitudinal images of the brachial artery were taken from the antecubital fossa. Baseline brachial artery diameter measurements of patients were made after being rested for at least 10 minutes. A sphygmomanometer cuff was inflated to 300 mmHg and this pressure was maintained for 4--5 minutes. The second measurement was made 45--60 seconds after removing the inflated cuff (reactive hyperemia). Patients had 15 minutes rest. Then, 0.5 mg diluted glyceryl trinitrate (GTN or nitroglycerine) was administered and the final measurement was made after 3--4 minutes. Vessel diameters and flow rates measured after reactive hyperemia and administration of GTN were compared with resting values. FMD results were calculated according to the method described by Celermajer et al. ([@j_jomb-2016-0030_ref_019], [@j_jomb-2016-0030_ref_020]). Normal healthy FMD % response was accepted as 7--10 ([@j_jomb-2016-0030_ref_021], [@j_jomb-2016-0030_ref_022]).

Analysis of data was done with SPSS statistical analysis software (version 20.0; SPSS Inc, Chicago, IL, USA). Results were expressed as means ± SD or median and interquartile range. Hs-CRP, ADMA, e-NOS, levels were logarithmically transformed to achieve normal distributions. General linear measurement analyses were used for anthropometric and metabolic parameters before and after adjustments for obesity, HDL lowness or group means were compared using analysis of covariance (ANCOVA). Power analysis was done by the General Linear Model where observed powered \> 0.8 is defined high power, \> 0.14 is defined large effect. Cut-off values for HDL cholesterol \< 1.01 μmol/L for men and \< 1.27 mmol/L for females were defined as low; LDL cholesterol \> 3.36 mmol/L was defined as high; triglyceride level \> 2.26 mmol/L was defined as high; hypertension was defined as SBP/DBP ≥ 140/90 mmHg; obesity was defined as BMI \> 30 kg/m^2^ ([@j_jomb-2016-0030_ref_014]). Because of the variability in HDL levels and obesity ratio among genders, analysis was done before and after adjustment for the confounders. Correlation analysis was done by Pearson correlation analysis after adjustment for obesity and HDL lowness. Multiple stepwise regression analysis was applied to predict the variables that independently and significantly contributed to the dependent variable (FMD). All analyses were two-tailed, and *P*-values less than 0.05 were considered statistically significant.

Results {#j_jomb-2016-0030_s_003}
=======

Clinical characteristics of 92 subjects according to the ESC- risk score system were summarized in *[Table I](#j_jomb-2016-0030_tab_001){ref-type="table"}*. Mean age of female and male subjects was similar (45±6 vs 47±7, P \> 0.05). Incidence of hypertension was 12% for females and 33% for males (P \> 0.05). Thirty-six percent of females and 54% of males were smoker (P=0.035). Total cholesterol levels of females and males were 5.61±1.03 mmol/L and 5.48±1.14 mmol/L respectively, P \> 0.05).

###### 

Patient characteristics among genders according to the ESC risk score system.

                               Female N=49   Male N=43   *P*-Value
  ---------------------------- ------------- ----------- -----------
  Age                          45±6          47±7        NS
                                                         
  Hypertension (%)             12.2          32.6        0.023
                                                         
  Smoking (%)                  32.7          53.5        0.035
                                                         
  Total Cholesterol (mmol/L)   5.61±1.03     5.48±1.14   NS

Data are means ± SD. P values were calculated using student's t test analysis. Noncategorical parameters were compared by chi-square test. NS: not significant, significance level: P\<0.05

Patient characteristics among genders which were not included in the ESC risk score system are seen in *[Table II](#j_jomb-2016-0030_tab_002){ref-type="table"}*; the prevalence of family history, LDL and triglyceride highness were 59.2%, 44.9%, 10.6% for women and 53.5%, 62.8%, 18.6% for men, respectively. There was a significant difference for HDL lowness with 23.4% for women and 34.9% for men, respectively (X^2^=90.000, P=0.000). Obesity ratio differed between genders with a higher ratio for males (16.3% vs 45.2%, respectively). The prevalence of impaired FMD was 51% for females and 46.5% for men, respectively. The distributions of e-NOS, ox-LDL, ADMA, CRP and e-selectin are seen in *[Figure 1](#j_jomb-2016-0030_fig_001){ref-type="fig"}*. Endothelial nitric oxide synthase (e-NOS), oxidized LDL (ox-LDL) and high sensitive CRP (hs-CRP) levels significantly differed between genders. Males had higher median and mean levels of e-NOS (P=0.018), OX-LDL (P=0.000) and hs-CRP (P=0.021). However, there were no significant differences for ADMA, e-selectin, sialic acid, vWF, ADP slope and ADP amplitude % among genders (*[Table III](#j_jomb-2016-0030_tab_003){ref-type="table"}*). e-NOS activity and ox-LDL levels remained significant after adjustment for HDL lowness and obesity (P=0.036, P=0.004, respectively).

![Distribution of e-NOS, ox-LDL, ADMA, CRP and E-Selectin across gender. Results were based on 45 female and 42 male subjects. NS, Not significant. Data represent median and interquartile range. o, Outliners. P values were calculated using Student's t test and values for ADMA, NOS, CRP levels were logarithmically transformed before analysis. Nontransformed values are shown in the graphs.](jomb-36-062-g001){#j_jomb-2016-0030_fig_001}

###### 

Patient characteristics among genders which are not included in the ESC risk score system.

                                    Female N=49   Male N=43   *P*-Value
  --------------------------------- ------------- ----------- ---------------------
  Family history (%)                59.2          53.5        NS
  HDL lowness                                                 X2=90.000/0.000
    \< 1.27 mmol/L (%)              23.4          --          
    \< 1.01 mmol/L (%)                            34.9        
  LDL \> 3.36 mmol/L (%)            44.9          62.8        NS
  Triglyceride \> 2.26 mmol/L (%)   10.6          18.6        NS
  Obesity (BMI \> 30 kg/m^2^) (%)   16.3          45.2        X^2^ = 9.059 /0.003
  First diameter (mm)               3.57±0.6      4.14±0.8    0.000
  Second diameter (mm)              3.89±0.7      4.50±0.7    0.000
  FMD (mm)                          3.97±0.7      4.64±0.8    0.000

Noncategorical parameters were expressed as number or percentage and compared by chi-square test. NS: not significant

###### 

Endothelial dysfunction biomarkers gender adjusted for obesity, HDL levels.

                         Female                Male                    P-Value[^a^](#j_jomb-2016-0030_fn_001){ref-type="table-fn"}   P-Value[^b^](#j_jomb-2016-0030_fn_002){ref-type="table-fn"}
  ---------------------- --------------------- ----------------------- ------------------------------------------------------------- -------------------------------------------------------------
  CRP (mg/L)             1.35 (0.50--2.20)     1.45 (0.92-- 3.33)      0.021                                                         NS
  Oxidized LDL (ng/mL)   2.35±1.16             3.64±1.67               0.000                                                         0.004
  ADMA (μmol/L)          0.15 (0.07--0.45)     0.12 (0.06--0.35)       NS                                                            NS
  E-Selectin (ng/mL)     2.09±1.31             3.00±1.24               0.065                                                         NS
  vWF (mU/mL)            1499.9±700.2          1362.2±682.7            NS                                                            NS
  e-NOS (pg/mL)          60.81 (44.4--131.9)   145.01 (58.1-- 276.3)   0.018                                                         0.036
  ADP E (%)              61.12±9.05            58.55±11.74             NS                                                            NS
  ADP A (%)              77.98±13.01           72.23±13.23             0.056                                                         NS
  Sialic acid (mmol/L)   1.50±0.7              1.51±0.8                NS                                                            NS

Data are presented as means ±SD or as median (interquartile range) for non-normally distributed variables. *P* values were calculated using ANCOVA, and values for CRP, ADMA and NOS levels were logarithmically transformed before analysis. Nontransformed values are shown. NS: not significant, significance level: P\<0.05

represents unadjusted P -- Value across gender

represents P -- Value adjusted for obesity and HDL levels

We next analyzed whether the presence of obesity and HDL lowness would modulate endothelial function. To test this hypothesis, first, we compared the levels of endothelial dysfunction biomakers among genders before and after adjustment for obesity and HDL levels (*[Table III](#j_jomb-2016-0030_tab_003){ref-type="table"}*). Male subjects had significantly higher CRP (P=0.021), OX-LDL (P=0.000), e-NOS (P=0.018) levels than female counterparts for the unadjusted model; only ox-LDL and e-NOS levels remained significant after adjustment for obesity and HDL lowness (P=0.004, P=0.036 respectively). ADP E and ADP A which show platelet function were decreased in men as compared to female counterparts but this decline did not reach any significance. To check our significant results, we conducted a power analysis and the effect size to show the statistical power. The effect of this size (.417 partial eta squared) to be detected (99% chance) as significant at the (P=0.001).

We next examined whether the difference in endothelial dysfunction biomarkers between genders might be confounded by FMD, obesity and HDL lowness. To argue this hypothesis, we compared the same endothelial dysfunction biomarkers across FMD between genders before and after adjustment for confounders (*[Table IV](#j_jomb-2016-0030_tab_004){ref-type="table"}*). In subjects with normal FMD, males had higher ox-LDL as compared to females before adjustment (P=0.004); sialic acid levels were significantly lower for same counterparts in an adjusted model (P=0.045). In subjects with abnormal FMD, males had significantly higher ox-LDL than females in both unadjusted and adjusted models (P=0.008, P=0.019 respectively). Platelet aggregation marker ADP A showed a significant decrease in males compared to females only after an adjustment model (P=0.020). Then, we compared the same biomarkers among FMD for each gender. In females, e-NOS levels were significantly lower for subjects with endothelial dysfunction before adjustment (P=0.028) and the significance did not remain after adjustment. In males, sialic acid levels were significantly higher for subjects with endothelial dysfunction only after adjustment for confounders (P=0.038).

###### 

Endothelial dysfunction biomarkers gender adjusted for obesity, HDL levels.

                                Female                                                                   P-Value[^a^](#j_jomb-2016-0030_fn_003){ref-type="table-fn"}   Male                                                              P-Value[^b^](#j_jomb-2016-0030_fn_004){ref-type="table-fn"}
  ----------------------------- ------------------------------------------------------------------------ ------------------------------------------------------------- ----------------------------------------------------------------- -------------------------------------------------------------
  Endothelial function normal                                                                                                                                                                                                            
    CRP (mg/L)                  1.12 (0.55--2.72)                                                        NS                                                            1.79 (1.09--2.98)                                                 NS
    Oxidized LDL (ng/mL)        2.41±1.21                                                                0.004                                                         3.85 ±1.88                                                        NS
    ADMA (μmol/L)               0.36 (0.09--0.61)                                                        NS                                                            0.12 (0.06--0.33)                                                 NS
    E-Selectin (ng/mL)          2.18±1.43                                                                NS                                                            2.72±1.58                                                         NS
    vWF (mU/mL)                 1559.13±646.62                                                           NS                                                            1300.16±748.91                                                    NS
    e-NOS (pg/mL)               77.7 (55.9--218.8)[^a^](#j_jomb-2016-0030_fn_003){ref-type="table-fn"}   NS                                                            145.1 (58.1--281.8)                                               NS
    ADP E (%)                   60.69±8.98                                                               NS                                                            60.36±12.05                                                       NS
    ADP A (%)                   80.96±10.59                                                              NS                                                            74.05±14.45                                                       NS
    Sialic acid (mmol/L)        45.13±18.29                                                              NS                                                            41.52±21.69[^d^](#j_jomb-2016-0030_fn_006){ref-type="table-fn"}   
  Endothelial dysfunction                                                                                                                                                                                                                
    CRP (mg/L)                  1.43 (0.46--2.04)                                                        NS                                                            1.31 (0.71-- 4.11)                                                NS
    Oxidized LDL (ng/mL)        2.29±1.13                                                                0.008                                                         3.40±1.40                                                         0.019
    ADMA (μmol/L)               0.11 (0.06-0.20)                                                         NS                                                            0.14 (0.05-0.89)                                                  NS
    E-Selectin (ng/mL)          1.54±1.13                                                                NS                                                            2.04±1.13                                                         NS
    vWF (mU/mL)                 1438.03 ±761.60                                                          NS                                                            1433.48±608.9                                                     NS
    e-NOS (pg/mL)               50.4 (30.8--94.7)[^a^](#j_jomb-2016-0030_fn_003){ref-type="table-fn"}    NS                                                            135.7 (54.0--239.9)                                               NS
    ADP E (%)                   61.60±9.32                                                               NS                                                            56.17±11.25                                                       NS
    ADP A (%)                   74.69±14.81                                                              NS                                                            69.84±11.43                                                       0.020
    Sialic acid (mmol/L)        52.78±25.48                                                              NS                                                            52.80±24.70[^d^](#j_jomb-2016-0030_fn_006){ref-type="table-fn"}   NS

Data are presented as means ± SD or as median (interquartile range) for non-normally distributed variables.

P values were calculated using student's t test analysis, and values for CRP ADMA and NOS levels were logarithmically transformed before analysis. Nontransformed values are shown. ^c^ represents P, Value after adjustment for obesity and HDL, NS: Not significant, significance level: P\<0.05

represents comparison of e-NOS levels among endothelial function for female gender (P=0.028 before adjustment for obesity and HDL, P=0.065 after adjustment for confounders)

represents P Value for unadjusted levels

represents comparison among endothelial function for male gender (P=0.038 for adjusted level)

The intercorrelations between endothelial dysfunction biomarkers with and without adjustments for obesity and HDL lowness are shown in *[Table V](#j_jomb-2016-0030_tab_005){ref-type="table"}*. E-selectin/e-NOS (r=.366, P\<0.001) and e-NOS/ox-LDL (r=0.360, P\<0.001) significantly and positively correlated with each other before adjustment. ADMA significantly but negatively correlated with e-NOS (r=\<0.298, P\<0.01), e-selectin (r=−0.361, P\<0.001) and ox-LDL (r=−0.351, P\<0.001) before adjustment. Notably, a relationship between e-selectin/e-NOS (r=0.344, P\<0.01), ox-LDL/e-NOS (r=0.366, P\<0.01) and negative relationships between e-selectin/ADMA (r=−0.266, P\<0.01), ox-LDL/ADMA (r=−0.312, P\<0.01) remained significant after adjustments for the confounders.

###### 

Correlations (r) between endothelial dysfunction biomarkers with and without adjustment for confounders[^a^](#j_jomb-2016-0030_fn_009){ref-type="table-fn"}

                                                                   e-NOS                                                          E-Selectin                                                      ox-LDL                                                          CRP                                                          ADMA
  ---------------------------------------------------------------- -------------------------------------------------------------- --------------------------------------------------------------- --------------------------------------------------------------- ------------------------------------------------------------ ---------------------------------------------------------------
  *Unadjusted*                                                                                                                                                                                                                                                                                                                 
  *e*-*NOS*                                                        1.000                                                          0.366[^\*\*^](#j_jomb-2016-0030_fn_010){ref-type="table-fn"}    0.360[^\*\*^](#j_jomb-2016-0030_fn_010){ref-type="table-fn"}    0.144                                                        -0.298[^\*^](#j_jomb-2016-0030_fn_012){ref-type="table-fn"}
  *E*-*Selectin*                                                   0.366[^\*\*^](#j_jomb-2016-0030_fn_010){ref-type="table-fn"}   1.000                                                           0.136                                                           0.218[^\*^](#j_jomb-2016-0030_fn_012){ref-type="table-fn"}   -0.361[^\*\*^](#j_jomb-2016-0030_fn_010){ref-type="table-fn"}
  *ox*-*LDL*                                                       0.360[^\*\*^](#j_jomb-2016-0030_fn_010){ref-type="table-fn"}   0.136                                                           1.000                                                           0.033                                                        -0.351[^\*\*^](#j_jomb-2016-0030_fn_010){ref-type="table-fn"}
  *CRP*                                                            0.144                                                          0.218[^\*^](#j_jomb-2016-0030_fn_012){ref-type="table-fn"}      0.033                                                           1.000                                                        -0.017
  *ADMA*                                                           -0.298[^\*^](#j_jomb-2016-0030_fn_012){ref-type="table-fn"}    -0.361[^\*\*^](#j_jomb-2016-0030_fn_010){ref-type="table-fn"}   -0.351[^\*\*^](#j_jomb-2016-0030_fn_010){ref-type="table-fn"}   -0.017                                                       1.000
  *vWF*                                                            0.224                                                          0.038                                                           0.061                                                           0.140                                                        -0.125
  *ADP E*                                                          0.025                                                          -0.013                                                          -0.117                                                          0.070                                                        0.206
  *ADP A*                                                          -0.036                                                         0.017                                                           -0.203                                                          0.047                                                        0.182
  *Sialic acid*                                                    -0.082                                                         -0.206                                                          0.085                                                           -0.130                                                       0.079
  *FMD*                                                            0.122                                                          0.213[^\*^](#j_jomb-2016-0030_fn_012){ref-type="table-fn"}      0.225[^\*^](#j_jomb-2016-0030_fn_012){ref-type="table-fn"}      0.146                                                        -0.010
                                                                                                                                                                                                                                                                                                                               
  *Adjusted*[^a^](#j_jomb-2016-0030_fn_009){ref-type="table-fn"}                                                                                                                                                                                                                                                               
  e-NOS                                                            1.000                                                          0.344[^\*^](#j_jomb-2016-0030_fn_012){ref-type="table-fn"}      0.366[^\*^](#j_jomb-2016-0030_fn_012){ref-type="table-fn"}      0.077                                                        -0.204
  E-Selectin                                                       0.344[^\*^](#j_jomb-2016-0030_fn_012){ref-type="table-fn"}     1.000                                                           0.459[^\*\*^](#j_jomb-2016-0030_fn_010){ref-type="table-fn"}    0.180                                                        -0.266[^\*^](#j_jomb-2016-0030_fn_012){ref-type="table-fn"}
  ox-LDL                                                           0.366[^\*^](#j_jomb-2016-0030_fn_012){ref-type="table-fn"}     0.459[^\*\*^](#j_jomb-2016-0030_fn_010){ref-type="table-fn"}    1.000                                                           0.085                                                        -0.312[^\*^](#j_jomb-2016-0030_fn_012){ref-type="table-fn"}
  CRP                                                              0.077                                                          0.180                                                           0.085                                                           1.000                                                        0.115
  ADMA                                                             -0.204                                                         -0.266[^\*^](#j_jomb-2016-0030_fn_012){ref-type="table-fn"}     -0.312[^\*^](#j_jomb-2016-0030_fn_012){ref-type="table-fn"}     0.115                                                        1.000
  vWF                                                              0.158                                                          0.104                                                           -0.095                                                          0.127                                                        0.009
  ADP E                                                            0.054                                                          -0.103                                                          -0.088                                                          0.040                                                        0.232
  ADP A                                                            -0.052                                                         -0.061                                                          -0.103                                                          -0.007                                                       0.199
  Sialic acid                                                      -0.055                                                         -0.158                                                          -0.096                                                          -0.035                                                       0.069
  FMD                                                              -0.001                                                         0.223                                                           -0.034                                                          -0.012                                                       -0.046

Values for CRP, ADMA and e-NOS levels were logarithmically transformed before analysis.

Obesity, HDL lowness

P\<0.001

P\<0.01

Finally, we performed a stepwise multiple logistic regression analysis to identify variables that independently and significantly contributed to the presence of endothelial dysfunction which was detected by FMD (*[Table VI](#j_jomb-2016-0030_tab_006){ref-type="table"}*). In a univariate analysis, decreased levels of e-NOS were associated with FMD in the female gender \[odds ratio (OR) 0.3, P \< 0.05\]. Further, in a multivariate logistic regression model, after adjustment for other risk factors, e-NOS was independently associated with FMD among females \[odds ratio (OR) 0.13, P \<0.05\].

###### 

Multiple stepwise logistic regression analysis relating e-NOS level to the presence of FMD across gender

  Models                        Female                Male                         
  ----------------------------- --------------------- ------- -------------------- ----
  A. e-NOS level                                      0.038   0.8 (0.4--1.5)       NS
   Model 1A: e-NOS level only   0.3 (0.1--0.9)                                     
    e-NOS level                                       0.030   0.93 (0.42--2.07)    NS
  Model 2A: Other endothelial   0.15 (0.03--0.83)     NS      0.35 (0.05--2.45)    NS
  dysfunction factors           0.96 (0.06--15.19)    0.050   0.09 (0.005--1.46)   NS
    e-NOS level                 74.7 (0.99--5589.5)   NS      0.85 (0.10--7.34)    NS
    Obesity                     0 (0--0)              NS      0.73 (0.31--1.71)    NS
    Triglyceride                0.91 (0.33--2.53)     0.016   1.92 (0.84--4.39)    NS
    HDL lowness                 0.24 (0.08--0.77)     NS      0.77 (0.35--1.72)    NS
    Oxidized LDL                0.53 (0.20--1.41)                                  
    ADMA                                                                           
    E-Selectin                                                                     

CI, Confidence interval; NS, not significant

Discussion {#j_jomb-2016-0030_s_004}
==========

In the present study, we investigated the association of endothelial dysfunction markers among genders in low CV risk individuals. Males have higher CRP, oxidized LDL, e-selectin and e-NOS levels than females. The positive relationship between e-selectin/e-NOS, ox-LDL/e-NOS, ox-LDL/e-selectin and negative relationship between ADMA/e-selectin and ADMA/ox-LDL were not affected by BMI and HDL lowness. However, the negative relationship between ADMA and e-NOS was confounded by BMI and HDL lowness in our study group. We also noted several important differences and associations among genders with respect to FMD. First, ox-LDL levels differed between genders in subjects with endothelial dysfunction and this difference was irrelevant of BMI and HDL lowness. Second, sialic acid levels (indicator of antioxidant defense system) were higher for males in endothelial dysfunction group compared to normal endothelial function group. Third, decrease in NOS activity was independently associated with FMD only for female gender. Our results underline that these biomarkers might capture different aspects of traditional predictors for each gender. Furthermore, untraditional cardiovascular risk factors affect each sex divergently even for low CV risk individuals which were not captured by the conventional risk score systems.

The prevalence of CVD is lower for women than men, and the effects of traditional biomarkers on CVD risk differ among them. Further, both of these factors might have an impact on CVD risk. The incidence of first cardiovascular events in men is higher for young men and is increasing very fast along with age, whereas women are 10 years behind them ([@j_jomb-2016-0030_ref_023]). A meta-analysis of 23 prospective studies revealed that apolipoproteins had moderately strong associations with risk of CHD, and these associations differred among men and women ([@j_jomb-2016-0030_ref_024]).

Although CVD has been known as a male disease, there is accumulating evidence on the different impact of major CV risk factors leading to a worse outcome in women, and female-specific risk factors are of influence in the onset of CVD ([@j_jomb-2016-0030_ref_025]). One of the modifiable risk factors of CVD is smoking. The global prevalence of smoking is almost 5 times higher for men than in women (48% vs 10%) ([@j_jomb-2016-0030_ref_026]). Recent researches showed that women who smoked had a 50% greater risk compared to male counterparts ([@j_jomb-2016-0030_ref_027]). Other prospective studies have shown that the prevalence of overweight in men and women depends on the development of the country and levels of BMI are mostly higher in men than women, however, the association between BMI and coronary heart disease is similar between men and women ([@j_jomb-2016-0030_ref_028]).

There are also some biological differences between men and women related to the size of arteries, coronary flow reserve and atheroma burden. Women have smaller carotid arteries ([@j_jomb-2016-0030_ref_029], [@j_jomb-2016-0030_ref_030]), with less plaque but more apparent stenosis ([@j_jomb-2016-0030_ref_031]) which may relate to differences in remodeling. Furthermore, it has been suggested that men have greater atheroma burden, more eccentric atheroma, and more diffuse epicardial endothelial dysfunction than women ([@j_jomb-2016-0030_ref_032]). However, women had slightly lower coronary vasodilatory reserves even with normal coronary angiographic results ([@j_jomb-2016-0030_ref_033]).

Current evidence suggests that endothelium has a crucial impact on CV risk and CV risk factors, including traditional or untraditional factors which were also related with endothelial dysfunction. Further, many of them are associated with overproduction of reactive oxygen species or increased oxidative stress ([@j_jomb-2016-0030_ref_034]) and contribute to atherosclerosis development and progression ([@j_jomb-2016-0030_ref_034]--[@j_jomb-2016-0030_ref_037]). Reactive oxygen species may also react with NO, reduce NO bioavailability and improve vascular damage ([@j_jomb-2016-0030_ref_037]). In agreement with this study and others, we observed significantly higher ox-LDL and e-NOS levels for men, before and after adjustment for confounders. Within male individuals, we stratified subjects according to FMD. Subjects with impaired FMD had higher sialic acid levels irrelevant of BMI and HDL lowness. In the same counterparts, ox-LDL levels and e-NOS level were decreased but this decline did not reach any significance. Increase in sialic acid levels which accompanied the decline in ox-LDL levels and e-NOS level might be the consequence of antioxidative and nitrosative defence systems. Iijima et al. stated that sialic acid consumes toxic hydrogen peroxide (H~2~O~2~) under physiologic conditions and acts as a radical scavenger ([@j_jomb-2016-0030_ref_038]). Other studies suggest that mucin -- a sialic acid -- storage-synthesis is induced by oxidative stress ([@j_jomb-2016-0030_ref_039]).

To the best of our knowledge, traditional CV risk factors affect both genders differently, and endothelial dysfunction is another contributor of atherosclerosis which is as a systemic disorder ([@j_jomb-2016-0030_ref_040]). It can be detected noninvasively by flow-mediated dilatation (FMD) in the brachial artery that is closely associated with endothelium dependent vasomotion in the coronary circulation ([@j_jomb-2016-0030_ref_040]).

In our study, impaired vascular tone defined by FMD differed between sexes which did not reach significance. We performed multiple logistic regression analyses to determine whether e-NOS would independently contribute to the presence of FMD beyond traditional and untraditional risk factors among genders. In a univariate analysis, we observed a significant association of e-NOS level with the presence of impaired FMD only in females. When taking other risk factors into account, the picture did not change for both genders and the e-NOS level remained significant for females. There are lots of studies demonstrating that estrogen markedly improves endothelium-dependent vasodilator responses to various physiological stimuli. This effect is likely mediated through the activation of endothelial nitric oxide synthase and the antioxidant effect of estrogen ([@j_jomb-2016-0030_ref_041]--[@j_jomb-2016-0030_ref_042]). Our female individuals are in their late forties and might have decrease in estrogen levels. There were also significant correlations between ox-LDL and e-NOS levels, and negative significant correlations between ox-LDL and ADMA levels before and after adjustment for confounders which support the relationship between oxidative stress and vascular function.

There were also several abnormalities which might favour platelet activation that have been reported in CVD, including endothelial dysfunction ([@j_jomb-2016-0030_ref_043]) and increased oxidative stress ([@j_jomb-2016-0030_ref_035]). Platelet activation resulting from disrupted plaque might be another marker for atherosclerosis. Gremmel et al. stated that females express significantly more pronounced formation of leukocyte-platelet aggregates than males ([@j_jomb-2016-0030_ref_044]). Cowman et al. showed that age related changes in platelet function were more profound in women than in men indicating that age and gender significantly impact on platelet interactions with VWF. Some researchers showed that vWF levels increased during the acute phase of endothelial dysfunction ([@j_jomb-2016-0030_ref_045]). In our study, ADP amplitude was higher in female than male subjects. Further, ADP amplitude was also higher in females than males for the endothelial dysfunction group after adjustment for confounders. We also found vWF level higher in females as compared to male counterparts but this increase remained insignificant. vWF showed an inverse pattern across genders among endothelial function; it decreased for female whereas increased for male which was not significant.

We acknowledge some of the limitations of this study. Patients taking any medication that could affect FMD and biomarker measurements including statins and antihypertensive agents were excluded from the study. Samples were collected from apparently healthy healthcare workers from Cerrahpasa Medical School who were in the same age range. Our sample size is small. Female individuals menapausal status were not evaluated. We defined endothelial dysfunction by FMD and determined risk score according to European Society of Cardiology score Risk Charts.

Conclusion {#j_jomb-2016-0030_s_005}
==========

Endothelial dysfunction biochemical markers differ between genders in low CV risk indivuals and the difference pointed out male gender had more risk for CVD than female that were not captured by ESC-score and other conventional risk score systems; however, additional studies are needed to verify these results in big populations. Our results underline the different medical practice for each gender might reduce chronic vascular diseases in early stages which may also decrease further healthcare costs.
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